Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies
暂无分享,去创建一个
L. Chow | C. Baik | K. Eaton | R. Martins | C. Rodriguez | R. Santana-Davila | Sylvia M. Lee | B. Goulart
[1] S. Karam,et al. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Dziadziuszko,et al. Abstract 3190: Genomic profiling of salivary gland tumors identifies novel and targetable alterations , 2016 .
[3] P. Stephens,et al. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations , 2016, Clinical Cancer Research.
[4] J. Gilbert,et al. Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. , 2016 .
[5] N. Schultz,et al. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer , 2016, Clinical Cancer Research.
[6] J. Blay,et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.
[7] D. Hayes,et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Odenthal,et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity , 2015, Oncotarget.
[9] P. Stephens,et al. Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies , 2014, The American journal of surgical pathology.
[10] S. Koyfman,et al. Biology and management of salivary gland cancers. , 2012, Seminars in radiation oncology.
[11] Chris Twelves,et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.
[12] D. Tu,et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer , 2010, Cancer.
[13] L. Mariani,et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. , 2009, Oral oncology.
[14] D. Hayes,et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Gilbert,et al. Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group , 2006, Head & neck.
[16] E. Lamont,et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Roodenburg,et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group , 2004, Head & neck.
[18] A. Colevas,et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. , 2003, Oral oncology.
[19] M. Airoldi,et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies , 2001, Cancer.
[20] R. Demicheli,et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] S. Rodenhuis,et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Verweij,et al. Cisplatin‐based chemotherapy in advanced adenoid cystic carcinoma of the head and neck , 1992, Head & neck.
[23] L. Licitra,et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients , 1991, Cancer.
[24] G. Budd,et al. Adenoid cystic carcinoma of the salivary gland: Sustained complete response to chemotherapy , 1983, Cancer.
[25] J. Hurley,et al. Complete response of a metastatic adenoid cystic carcinoma of the parotid gland to chemotherapy , 1981, Cancer.
[26] A. Garden,et al. Postoperative radiotherapy for malignant tumors of the parotid gland. , 1997, International journal of radiation oncology, biology, physics.